ContextCurrent treatment options for metastatic renal cell carcinoma (RCC) are limited and
there is a need to identify novel and effective therapies. Sunitinib malate is an oral
multitargeted tyrosine kinase inhibitor, which has shown activity in an initial study of cytokine-
refractory metastatic RCC patients. ObjectiveTo confirm the antitumor efficacy of sunitinib as
second-line treatment in patients with metastatic clear-cell RCC, the predominant cell type of
this malignancy. Design, Setting, and PatientsOpen-label, single-arm, multicenter clinical …